Cotadutide is an investigational dual agonist peptide currently under development for the management of type 2 diabetes mellitus. Functioning as a GLP-1 and glucagon receptor co-agonist, this therapeutic… Read more
Cotadutide is an investigational dual agonist peptide currently under development for the management of type 2 diabetes mellitus. Functioning as a GLP-1 and glucagon receptor co-agonist, this therapeutic agent works to enhance insulin secretion and regulate glucagon release to improve glycemic control. To support the rigorous analytical requirements of pharmaceutical development, laboratories rely on high-quality reference standards for Cotadutide, including its associated pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. These materials are essential for accurate impurity profiling, method validation, and ongoing quality control throughout the drug manufacturing process. By utilizing these precisely characterized reference materials, researchers can ensure compliance with regulatory standards and maintain the integrity of their analytical methods during the development and stability testing of this promising diabetic treatment.